These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11502203)

  • 1. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.
    Petersen HH; Hansen M; Schousboe SL; Andreasen PA
    Eur J Biochem; 2001 Aug; 268(16):4430-9. PubMed ID: 11502203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
    Sipley JD; Alexander DS; Testa JE; Quigley JP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
    Lin Z; Jiang L; Yuan C; Jensen JK; Zhang X; Luo Z; Furie BC; Furie B; Andreasen PA; Huang M
    J Biol Chem; 2011 Mar; 286(9):7027-32. PubMed ID: 21199867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
    Botkjaer KA; Fogh S; Bekes EC; Chen Z; Blouse GE; Jensen JM; Mortensen KK; Huang M; Deryugina E; Quigley JP; Declerck PJ; Andreasen PA
    Biochem J; 2011 Aug; 438(1):39-51. PubMed ID: 21635223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
    Pedersen AN; Høyer-Hansen G; Brünner N; Clark GM; Larsen B; Poulsen HS; Danø K; Stephens RW
    J Immunol Methods; 1997 Apr; 203(1):55-65. PubMed ID: 9134030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
    Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
    Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
    Debrock S; Declerck PJ
    Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases.
    Debrock S; Declerck PJ
    FEBS Lett; 1995 Dec; 376(3):243-6. PubMed ID: 7498551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
    Wind T; Jensen MA; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S; Declerck PJ
    Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1.
    Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y
    Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R; Petersen TE; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.